NXGL NEXGEL INC

NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday

NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday

LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced rescheduling its financial results conference call for the fourth quarter and full year 2023 to Monday, April 1st at 8:30 a.m. ET. The Company intends to file its Form 10-K with the SEC and issue a press release prior to the start of the call.

Adam Levy, CEO of NEXGEL, commented, “In light of the stock markets being closed to observe the Good Friday holiday, we are moving the reporting of our 2023 financial results to Monday morning before the market open. We hope this creates greater visibility and convenience for our shareholders.”

Fourth Quarter and Full Year 2023 Financial Results Conference Call

Date: Monday, April 1, 2024

Time: 8:30 a.m. ET

Live Call: 1 (U.S. Toll Free) or 4 (International)

Webcast:

For interested individuals unable to join the conference call, a replay will be available through April 15, 2024 by dialing 1 (U.S. Toll Free) or 1 (International). Participants must use the following code to access the replay of the call: 1155204. An archived version of the webcast will also be available for 90 days.

About NEXGEL, INC.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contacts:

Valter Pinto, Managing Director

KCSA Strategic Communications

212.896.1254



EN
27/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEXGEL INC

 PRESS RELEASE

NEXGEL Reports Second Quarter 2025 Financial Results

NEXGEL Reports Second Quarter 2025 Financial Results Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-ge...

 PRESS RELEASE

NEXGEL to Report Second Quarter 2025 Financial Results on August 12th

NEXGEL to Report Second Quarter 2025 Financial Results on August 12th Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2025, after the market close on August 12, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET ...

 PRESS RELEASE

NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardi...

NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Steve Ciardiello, CPA, to its Board of Directors. With more than 25 years of experience as a senior finance executive and current Chief Accounting Officer of Shutterstock, Inc. (NYSE:...

 PRESS RELEASE

NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Pr...

NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement LANGHORNE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 413,044 shares of its common stock (the “Shares”) at $2.30 a share. In a concurrent private placement, NEXGEL also agreed to issue to th...

 PRESS RELEASE

NEXGEL and STADA AG Announce Expansion of Partnership for North Americ...

NEXGEL and STADA AG Announce Expansion of Partnership for North America LANGHORNE, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced expanding its partnership with (“STADA”), a European leader in consumer health. The expansion includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks. As part of the agreement, STADA will advance $1 million to NEXGEL in non-dilutive...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch